A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia. [clinicaltrials:NCT00040677]

Bio2RDF uri

A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia. [clinicaltrials:NCT00040677]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00040677

Bio2RDF identifier

NCT00040677

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00040677

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

ICA-17043 is being deve ...... organ disease is anticipated.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

A Study of the Efficacy and Sa ...... ients With Sickle Cell Anemia.

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb) 12 Weeks [clinicaltrials_resource:f078b984d0a704a2d90b9ca7d606973b]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb) 12 Weeks [clinicaltrials_resource:27ba3609cc367fe30385afbda468e0ac]

The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb) 12 Weeks [clinicaltrials_resource:3101a556d239ce9c677ab73b42ca6a4f]

The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb) 12 Weeks [clinicaltrials_resource:49a0c614938876c2445feebe5b08e797]

The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb) 12 Weeks [clinicaltrials_resource:59d69877b7b5a47dead9778aa2bdb292]

The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb) 12 Weeks [clinicaltrials_resource:661826839505004bd11dce85a9b4e52a]

The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb) 12 Weeks [clinicaltrials_resource:7f7cd2f7fdebaec69f7d8b978a81c78b]

The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb) 12 Weeks [clinicaltrials_resource:9ea0b80233a2a5319a3d8ca2b8788464]

The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb) 12 Weeks [clinicaltrials_resource:c0d7f231f1ec640db538bb71b9a14401]

The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb) 12 Weeks [clinicaltrials_resource:dc975325646b27a8bc3df909bfea951f]

The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb) 12 Weeks [clinicaltrials_resource:ee639ea9beaedf5378920a9fee1ea4bc]

completion date [clinicaltrials_vocabulary:completion-date]

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Sickle Cell Disease [clinicaltrials_resource:34ae168553b3ce333cb59c050434aea2]

Sickle Cell Anemia [clinicaltrials_resource:b441a35faa800a129d39de5d87e14f55]

condition browse [clinicaltrials_vocabulary:condition-browse]

Anemia, Sickle Cell [clinicaltrials_resource:81f43d2a36d20ba99e346a5e466d1f35]

Anemia [clinicaltrials_resource:fc45c680042272ad16c9a1b778a8a14c]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Anemia, Sickle Cell [clinicaltrials_resource:81f43d2a36d20ba99e346a5e466d1f35]

Anemia [clinicaltrials_resource:fc45c680042272ad16c9a1b778a8a14c]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00040677 [clinicaltrials_resource:0f427c9defd1c77022e59dca57287aab]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2002-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

High dose ICA-17043 [clinicaltrials_resource:0e4ef051b06910d7a8dfa89f802ae92c]

Low Dose ICA-17043 [clinicaltrials_resource:27d980544f56b6a46504c9660a44e054]

Placebo [clinicaltrials_resource:bd4e6bd53b051565bae6460481d0b22f]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Hydroxyurea [clinicaltrials_resource:f82e4c9f89a991c5db967faf0b91fad2]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

ICA-17043

http://www.w3.org/2001/XMLSchema#string

anemia

http://www.w3.org/2001/XMLSchema#string

senicapoc

http://www.w3.org/2001/XMLSchema#string

sickle cell anemia

http://www.w3.org/2001/XMLSchema#string

sickle cell disease

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2011-07-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Icagen [clinicaltrials_resource:730b520ac12c76cae7fb1471bcb2a26c]

link [clinicaltrials_vocabulary:link]

For more information about Icagen [clinicaltrials_resource:158abc00d5f888cdbb84a96639b3b1de]

location [clinicaltrials_vocabulary:location]

Study Site [clinicaltrials_resource:874a895a72e7a983bddc990d71c2fae5]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00040677

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Phase II, Multicenter, Twelv ...... tients With Sickle Cell Anemia

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

ICA-17043-05

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Kenneth I Ataga, MD [clinicaltrials_resource:65cb759a4f31700bda287eeafe252fe6]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:be4cea82cb21bbda79c939a4d720315b]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2003-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

Greg Rigdon, Vice President New Product Development, Icagen [clinicaltrials_resource:0a3a8bfd5e5f3c3ed0fa16cf5ca5e079]

source [clinicaltrials_vocabulary:source]

Icagen [clinicaltrials_resource:730b520ac12c76cae7fb1471bcb2a26c]

start date [clinicaltrials_vocabulary:start-date]

2002-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00040677 study design [clinicaltrials_resource:d7c8f71a4e03449cc1a3f9046c2d8387]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00040677

verification date [clinicaltrials_vocabulary:verification-date]

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00040677

http://www.w3.org/2001/XMLSchema#string

title

A Study of the Efficacy and Sa ...... ients With Sickle Cell Anemia.

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

A Study of the Efficacy and Sa ...... . [clinicaltrials:NCT00040677]

@en